Valiant Laboratories Limited (NSE: VALIANTLAB, BSE: 543998) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹594 Cr, it ranks #1,907 by market cap among the 6,197 Indian listed companies on FinBizNet, and #27 of 63 in Pharmaceuticals. At ₹104.96 (as of 16 Nov 2026), the share price is 25.8% below its 52-week high of ₹141.38 and 112.0% above its 52-week low of ₹49.51. The share price is up 24.9% over one year and up 33.7% over three months.
| Current Price | ₹104.96 |
|---|---|
| Market Cap | ₹594 Cr |
| NSE Symbol | VALIANTLAB |
| BSE Code | 543998 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -1.20% |
| Return on Assets | 0.14% |
| 52-Week Range | ₹49.51 – ₹141.38 |
| 1-Year Price Change | +24.9% |
| 3-Month Price Change | +33.7% |
| Beta (1Y) | 0.61 |
| Headquarters | Mumbai, Maharashtra |
| Website | valiantlabs.in |
| Revenue | ₹117 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 0.4% |
| EPS (Basic) | ₹0.08 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Valiant Laboratories Limited reported revenue of ₹117 Cr in Q2 FY27, up 152.7% from ₹46 Cr in Q2 FY26 and up 1.3% from ₹115 Cr in Q1 FY27. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (up 105.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹46 Cr (Q2 FY26) to ₹117 Cr (Q2 FY27). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹117 Cr | ₹0 Cr | 0.4% |
| Q1 FY27 | ₹115 Cr | ₹21 Cr | 18.3% |
| Q4 FY26 | ₹92 Cr | ₹2 Cr | 1.9% |
| Q3 FY26 | ₹52 Cr | −₹7 Cr | −13.5% |
| Q2 FY26 | ₹46 Cr | ₹0 Cr | 0.4% |
| Q1 FY26 | ₹47 Cr | ₹2 Cr | 3.9% |
| Q4 FY25 | ₹58 Cr | ₹1 Cr | 1.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 74.94% of Valiant Laboratories Limited's shares as of Sept 2026, unchanged from Sept 2025.
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
1. Manufacturing of Chemicals Business-This segment manufactures paracetamol in various grades. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing of Chemicals Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Valiant Laboratories Limited | ₹594 Cr | n/m | -1.20% | ₹117 Cr | +24.9% |
Listed by market capitalisation. Ratios are shown for context only.
Valiant Laboratories Limited is trading at ₹104.96, with a market capitalisation of ₹594 Cr.
Valiant Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Valiant Laboratories Limited has a return on equity of -1.20%.
Valiant Laboratories Limited is listed on the NSE under the symbol VALIANTLAB and on the BSE under the scrip code 543998.
Valiant Laboratories Limited's share price is up 24.9% over one year and up 33.7% over three months. Its 52-week range is ₹49.51 to ₹141.38.
In Q2 FY27, Valiant Laboratories Limited reported revenue of ₹117 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.08 (consolidated, parsed from the company's exchange filing).
Valiant Laboratories Limited reported revenue of ₹117 Cr in Q2 FY27, up 152.7% from ₹46 Cr in Q2 FY26 and up 1.3% from ₹115 Cr in Q1 FY27.
Promoters held 74.94% of Valiant Laboratories Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.